The Role of Amyloid‐Beta in Blood and Cerebrospinal Fluid: Implications for Alzheimer’s Disease Diagnosis and Monitoring

Aβ levels in CSF remain a gold standard for early AD detection and disease monitoring. However, advancements in blood-based biomarker assays offer a less invasive and potentially scalable approach for population-level screening and longitudinal monitoring. Continued refinement of analytical techniques and standardization across studies are essential to establish the clinical utility of blood-based Aβ biomarkers in AD.